INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2010

Vitamin D3 non-significantly reduced relapse risk in patients with remitted Crohn's disease.

A randomized trial evaluated daily oral supplementation with 1,200 IU vitamin D3 versus placebo over 12 months in 94 patients with Crohn's disease in remission. Vitamin D3 elevated mean serum 25OHD from 69 nmol/L to 96 nmol/L after 3 months (P < 0.001). Clinical relapse occurred in 13% (6/46) of the vitamin D3 group versus 29% (14/48) of the placebo group, which did not reach statistical significance (P = 0.06).

Study type
Randomized controlled trial
Who was studied
94 patients with Crohn's disease in remission
What was measured
Clinical relapse of Crohn's disease

THE PAPER

Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

Jørgensen SP, Agnholt J, Glerup H, Lyhne S, Villadsen GE, Hvas CL, Bartels LE, Kelsen J, Christensen LA, Dahlerup JF. Aliment Pharmacol Ther, 2010.

PubMed 20491740 ↗DOI 10.1111/j.1365-2036.2010.04355.x ↗

Gut & microbiomeNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.